AU 55
Alternative Names: AU-55Latest Information Update: 05 Sep 2023
At a glance
- Originator Aurora BioPharma
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 05 Sep 2023 AU 55 is still in preclinical development for Haematological malignancies in USA (Parenteral) (Aurora Biopharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 12 Jul 2016 Preclinical trials in Haematological malignancies in USA (Parenteral) before July 2016